# InnovHeart S.r.l.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/innovheart-s-r-l

- Industry: Medical Devices & Equipment
- Headquarters: Milan, Italy
- Website: www.innovheart.com
- Total disclosed funding: $79M
- Latest round: Series C (Jan 27, 2022)
- Investors on record: 6

## About

InnovHeart S.r.l. specializes in heart valve therapy, developing innovative solutions to improve patient outcomes in mitral valve dysfunction treatment.Founded in 2015 and headquartered in Milan, Italy, InnovHeart S.r.l. focuses on delivering advanced heart valve therapies. The company has engaged in 2 deals, with its most recent funding round being a Series C investment of USD 55.00 mn in January 2022, led by China Grand Pharmaceutical and Healthcare Holdings Limited alongside other investors, generating a total amount raised of USD 55.00 mn. David Wilson serves as the CEO, guiding the firm's direction in the medical device sector.InnovHeart centers on the Saturn Transcatheter Mitral Valve Replacement (TMVR) system, designed to tackle the challenges of mitral valve dysfunction, especially in severe cases. The Saturn system has been through clinical trials, with the first trans-septal clinical trial implant announced in May 2024. The company aims to serve hospitals and healthcare providers across Europe and is working on expanding into the U.S. market, catering to patients with severe heart valve diseases who may not qualify for traditional surgical options.In 2018, InnovHeart reported revenue of USD 0 mn, while in 2022, its EBITDA was recorded at USD -11,290,267.50.Following its Series C funding round on January 27, 2022, where InnovHeart raised USD 55.00 mn, the company intends to utilize the funds for the development and commercialization of the Saturn TMVR Device, specifically targeting the Greater China market. InnovHeart is poised for expansion into new geographic regions to enhance its market presence.

## Funding rounds

- Series C, Jan 27, 2022, $55M — Panakes Partners, Indaco Venture Partners, China Grand Pharmaceutical and Healthcare Holdings Limited, Genextra
- Series B, Aug 7, 2020, $24M — Genextra S.p.A., Panakes Partners, Indaco Venture Partners, CDP Venture Capital

## Investors

- Genextra S.p.A. — Series B
- Panakes Partners (https://capitalatlas.ai/funds/panakes-partners) — Series B, Series C
- Indaco Venture Partners (https://capitalatlas.ai/funds/indaco-venture-partners) — Series B, Series C
- CDP Venture Capital (https://capitalatlas.ai/funds/cdp-venture-capital) — Series B
- China Grand Pharmaceutical and Healthcare Holdings Limited — Series C
- Genextra (https://capitalatlas.ai/funds/genextra) — Series C